IRIS

Lead and compounds (inorganic)

CASRN 7439-92-1 | DTXSID2024161

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (15 pp, 128 K) Last Updated: 07/08/2004
Information reviewed but value not estimated.

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (15 pp, 128 K)
Not assessed under the IRIS Program.

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (15 pp, 128 K) Last Updated: 09/26/1988

WOE Characterization Framework for WOE Characterization
B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986)
Basis:
  • Sufficient animal evidence. Ten rat bioassays and one mouse assay have shown statistically significant increases in renal tumors with dietary and subcutaneous exposure to several soluble lead salts. Animal assays provide reproducible results in several laboratories, in multiple rat strains with some evidence of multiple tumor sites. Short term studies show that lead affects gene expression. Human evidence is inadequate.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (15 pp, 128 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (15 pp, 128 K)

Not assessed under the IRIS Program.

Additional EPA toxicity information may be available by visiting the following sites:

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.